CHICAGO, April 8 /PRNewswire-FirstCall/ -- Advanced Life Sciences Holdings, Inc. , today announced the results from the Annual Meeting of Shareholders that it held today at its Woodridge headquarters.
At the meeting, the shareholders elected John L. Flavin, Richard A. Reck and Dr. Rosalie Sagraves to the Company’s Board of Directors each for a term of three years and ratified the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for fiscal year 2010. The shareholders also approved an amendment to the Company’s articles of incorporation to increase the number of authorized shares from 125,000,000 to 625,000,000 including an increase in the number of authorized shares of common stock from 120,000,000 to 620,000,000. Additionally, shareholders voted to provide 2,000,000 additional stock options for grant under the Company’s 2005 Stock Incentive Plan. Lastly, shareholders voted to authorize the Board of Directors to effect a reverse stock split of common stock at any time before April 8, 2011.
About Advanced Life Sciences
Advanced Life Sciences is a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, cancer and respiratory diseases. The Company’s lead candidate, Restanza, is a novel once-a-day oral antibiotic in late-stage development for the treatment of respiratory tract infections including CABP and biodefense pathogens including anthrax, plague and tularemia. For more information, please visit us on the web at www.advancedlifesciences.com or follow us on twitter at http://twitter.com/advancedlifesci.
CONTACT: Joe Camp of Advanced Life Sciences, +1-630-754-4352,
jcamp@advancedlifesciences.com
Web site: http://www.advancedlifesciences.com/
